Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 6/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3060116 | 0.81 | DAO (0.44) | DAOGPR35MEN1KMT2AALDH1A1 | |
| SCHEMBL16237271 | 0.78 | DAO (0.55) | DAOGPR35MEN1KMT2AALDH1A1 | |
| SCHEMBL3004459 | 0.74 | — | — | |
| SCHEMBL6964660 | 0.74 | — | — | |
| SCHEMBL8779802 | 0.73 | KDM4E (0.40) | DAOMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL1530004 | 0.72 | DAO (0.63) | DAOGPR35MEN1KMT2AALDH1A1 | |
| SCHEMBL899479 | 0.71 | GSK3B (0.61) | DAOGPR35MEN1KMT2AALDH1A1 | |
| SCHEMBL3175779 | 0.71 | ALDH1A1 (0.37) | ALDH1A1MAPTKDM4ELMNASMN1; SMN2 | |
| SCHEMBL17201685 | 0.70 | DAO (0.45) | DAOGPR35MEN1KMT2AALDH1A1 | |
| Bromide SCHEMBL8935164 | 0.70 | GSK3B (0.59) | DAOGPR35MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200216432-A1 | SULFONAMIDE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | KING'S COLLEGE LONDON (GB) | 2020-07-09 | — | — | US | disclosed |
| EP-3665164-A1 | SULFONAMIDE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Kings College London (GB) | 2020-06-17 | — | — | EP | disclosed |
| WO-2019030538-A1 | SULFONAMIDE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | KING'S COLLEGE LONDON (GB) | 2019-02-14 | — | — | WO | disclosed |
| WO-2019030538-A1 | SULFONAMIDE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | KING'S COLLEGE LONDON (GB) | 2019-02-14 | — | — | WO | disclosed |
| EP-0676395-B1 | Substituted N-heteroaroylguanidines, as inhibitors of sodium-hydrogen exchange, as antiarrhythmic agents and as inhibitors of the proliferation of cells | HOECHST AG (DE) | 2003-09-03 | — | — | EP | disclosed |
| CN-1073988-C | Substituted heteroaromatic acylguanidines, process for their preparation, their use as medicaments and medicaments containing them | HOECHST AG (DE) | 2001-10-31 | — | — | CN | disclosed |
| US-5698581-A | ANTIISCHEMIC AGENTS, ANTIARRHYTHMIA AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-12-16 | — | — | US | disclosed |
| CN-1117044-A | Substituted heteroaromatic acylguanidines, process for their preparation, their use as medicaments and medicaments containing them | HOECHST AG (DE) | 1996-02-21 | — | — | CN | disclosed |
| EP-0676395-A2 | Substituted N-heteroaroylguanidines, as inhibitors of sodium-hydrogen exchange, as antiarrhythmic agents and as inhibitors of the proliferation of cells | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216432-A1 | SULFONAMIDE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | JAK2, STAT3, STAT5A | DAO 4229/4885GPR35 3163/4885MEN1 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.